Post_template - Page 3 of 10

OncoOne Announces Formation of Clinical Advisory Board to Support Development of ON104 for Chronic Inflammatory Diseases.

PDF Vienna, Austria – March 12, 2024 – OncoOne, a biotechnology company focused on discovering precision medicines for cancer and autoimmune diseases, announced today the formation of a clinical advisory board to provide strategic and clinical insights for the company’s lead program in immunology, ON104. ON104 is

Check out our brand-new oxMIF mechanism of action video

Our team at OncoOne is developing a pipeline of therapeutic antibodies capable of targeting Hashtag#oxMIF, the disease-related isoform of MIF discovered by our founders. Our mission is to leverage our breakthrough discovery and oxMIF’s potential as a target for systemic treatment of rheumatoid arthritis, nephritis,

Bio CEO & Investor Conference, February 26-27, 2024, New York, NY, US

OncoOne’s CEO, Randolf Kerschbaumer, heads to NYC for the BIOCEO24 on Feb 26-27. A key event for investors and biotech leaders, Randolf will discuss licencing and partnership opportunities for our oxMIF-targeting antibody assets, ON104 for inflammation and ON203 for immuno-oncology. OncoOne is also making strides

JP Morgan Conference, January 8-11, 2024, San Francisco, CA, US

Our CEO, Randolf Kerschbaumer, and CSO, Michael Thiele, are looking forward to connecting with the biotech, pharma, VC, and investor community at JP Morgan Healthcare Conference! Please feel free to reach out.

TRP 2023: Targeted Radiopharmaceuticals Summit, December 5-7, 2023, Berlin, DE

OncoOne invites you to join us at the Targeted Radiopharmaceuticals Summit Europe in Berlin from December 5 to 7. Our VP CMC Friedmund Bachmann will be sharing the latest insights on OncoOne’s innovative PreTarg-it® platform on Tuesday, December 6, 13:00 CET at TRP23. Explore how

PEGS 2023 Europe, October 13-16, 2023, Lisbon, PR

Join OncoOne at PEGS Europe in Lisbon from November 14 to 16. Our CTO Alexander Schinagl will be presenting the latest insights on OncoOne’s PreTarg-it® platform on Tuesday, November 14, at PEGS23. Discover how our Modular PreTargit Platform enhances RIT for challenging cancers, improving therapeutic

Festival of Biologics, October 10-12, 2023, Basel, CH

Will you be joining us at the Festival of Biologics in Basel next week? Don’t miss the presentation by our CSO, Michael Thiele, titled “Antibody ON104: Alleviating Inflammation by Neutralizing Key Pathological Functions of oxMIF.” Also, be sure to visit our poster #76, where our

BIO EUROPE 2023, October 6-8, 2023, Munich, DE

OncoOne’s leadership team, including Randolf Kerschbaumer, CEO, Alexander Schinagl, CTO, and Christine Landlinger-Schubert, VP Preclinical and Translational R&D, will be present at BioEurope from November 6-8 in Munich, Germany. Feel free to reach out and connect with us to explore OncoOne’s innovative antibody pipeline targeting

Publication: Drug Target Review Issue 3 – Features our CEO

Our thanks to Drug Target Review for featuring an article by our CEO and Co-Founder, Randolf Kerschbaumer, highlighting novel capabilities that address elusive therapeutic targets and their impact on the treatment paradigm for patients living with cancer. Download the article here to learn more about

EANM: Annual Congress of the European Association of Nuclear Medicine, September 9-13, 2023, Vienna, AT

We are pleased to announce that our VP of CMC, Friedmund Bachmann, and Scientist Alejandro Puchol will be presenting at the upcoming Congress of the European Association of Nuclear Medicine (EANM23) in Vienna, taking place from September 9-13, 2023. 1. “Pretargeted Radioimmunotherapy with an Anti-oxMIF/HSG